Conference Coverage
Conference Coverage
New direct-acting antivirals for HCV perform well in real world
Discontinuation rates for the new direct-acting antivirals are “not a major issue” in real world clinical practice.
Conference Coverage
VIDEO: Ledipasvir/sofosbuvir highly effective in treatment-naive HCV GT1
Combination treatment with ledipasvir/sofosbuvir is highly effective for treatment-naive hepatitis C virus genotype 1 patients in routine medical...
Conference Coverage
VIDEO: PALBI score sharpened liver cancer prognosis
Conference Coverage
Lusutrombopag is effective for thrombocytopenia in liver disease
Key clinical point: In a phase III trial, lusutrombopag was found to reduce the need for platelet transfusion in chronic liver disease patients...
Conference Coverage
Pan-caspase inhibitor controls cirrhosis-associated portal hypertension
Emricasan, a caspase inhibitor, achieves a significant reduction in portal pressure among patients with cirrhosis and severe portal hypertension,...
Conference Coverage
Eight-week, three-drug regimen produces SVR over 90% in HCV
A triple antiviral combination with direct-acting antiviral agents was associated with high rates of sustained virologic response across all three...
Conference Coverage
Gastrointestinal and liver diseases remain substantial public health burden
Hospital admissions and associated costs for Clostridium difficile infection, inflammatory bowel disease, and liver disease all rose substantially...
Conference Coverage
IDWeek: Despite better drugs, HCV deaths keep rising
Despite better therapies, deaths from hepatitis C virus infection continue to rise, indicating poor penetrance of medications and care to patients...
Conference Coverage
Daclatasvir plus sofosbuvir safe and effective in HCV/HIV coinfection
Daclatasvir and sofosbuvir therapy achieves sustained virologic response in hepatitis C and HIV coinfection, without compromising HIV suppression...
Conference Coverage
DDW: Single daily pill knocks out HCV in prior nonresponders
Key clinical point: A fixed dose combination of grazoprevir and elbasvir, with or without ribavirin, was effective in patients with previously...